Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis
- PMID: 33593401
- PMCID: PMC7885348
- DOI: 10.1186/s12969-021-00502-8
Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis
Abstract
Background: Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA.
Methods: JIA patients (n = 151) followed by the Pediatric Rheumatology Core at Children's Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 19), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels > 0.2 ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71).
Results: Elevated 14-3-3η levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis.
Conclusion: Serum 14-3-3η can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3η does not appear to correlate with disease activity in JIA.
Keywords: 14–3-3η(eta); Biomarker; CCP antibody; Juvenile idiopathic arthritis; Rheumatoid factor.
Conflict of interest statement
Multiple researchers involved in our study are or were Quest Diagnostics employees and one employee had stock at Quest Diagnostics in the last year.
Iris Reyhan MD.
Conflict of Interest: None.
Olga S. Zhukov, MS MB (ASCP).
Conflict of Interest: Quest Diagnostics Employee, stock, stock options.
Robert J. Lagier, MS.
Conflict of Interest: Quest Diagnostics Employee.
Robert F. Bridgforth.
Conflict of Interest: former Quest Diagnostics Employee.
Gary J. Williams, PhD.
Conflict of Interest: former Quest Diagnostics Employee, stocks.
Joanna M. Popov, MD PhD.
Conflict of Interest: Quest Diagnostics Employee.
Stanley J. Naides, MD.
Conflict of Interest: formerly Quest Diagnostics Employee, stock, stock options.
Andreas Reiff, MD.
Conflict of Interest: None.
Figures
Similar articles
-
Evaluation of anti-cyclic citrullinated peptide antibodies may be beneficial in RF-negative juvenile idiopathic arthritis patients.Clin Rheumatol. 2016 Mar;35(3):601-7. doi: 10.1007/s10067-015-2971-5. Epub 2015 May 21. Clin Rheumatol. 2016. PMID: 25994613
-
Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype.Arthritis Rheumatol. 2017 Jul;69(7):1387-1395. doi: 10.1002/art.40117. Epub 2017 Jun 5. Arthritis Rheumatol. 2017. PMID: 28380667
-
14-3-3η Protein as a Potential Biomarker in Juvenile Idiopathic Arthritis.Pediatr Rep. 2021 Jan 25;13(1):65-71. doi: 10.3390/pediatric13010008. Pediatr Rep. 2021. PMID: 33504004 Free PMC article.
-
14-3-3η: a novel biomarker platform for rheumatoid arthritis.Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-35-9. Epub 2014 Oct 30. Clin Exp Rheumatol. 2014. PMID: 25365087 Review.
-
Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology.Curr Rheumatol Rep. 2008 Apr;10(2):156-63. doi: 10.1007/s11926-008-0027-4. Curr Rheumatol Rep. 2008. PMID: 18460272 Review.
Cited by
-
14-3-3 Eta protein as a novel biomarker in early detection of uveitis in Egyptian juvenile idiopathic arthritis and rheumatoid arthritis patients: Diagnostic and prognostic value.Rheumatol Immunol Res. 2025 Jan 9;5(4):217-226. doi: 10.1515/rir-2024-0030. eCollection 2024 Dec. Rheumatol Immunol Res. 2025. PMID: 39802549 Free PMC article.
References
-
- Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63(4):465–482. doi: 10.1002/acr.20460. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous